Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05126433 · ClinicalTrials.gov registry record · Phase 2
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05126433 is a Phase 2 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT05126433, a Phase 2 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
Interventions
- DRUG Lurbinectedin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05126433
The ClinicalTrials.gov registry entry for NCT05126433 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurbinectedin is the first listed.
NCT05126433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05126433 about?
NCT05126433 is a clinical study titled "Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors". This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
What is the current status of trial NCT05126433?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2022-03-03. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT05126433?
The interventions under investigation include: Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05126433?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.